In mid-2019, a new R&D&I collaboration programme begins in LABORATORIOS ERN.
The board of directors plans to extend the traditional R&D of LABORATORIOS ERN with a new commitment for the investment and development of innovative technologies in the healthcare sector, collaborating with centres of excellence, hospitals, universities, and start-ups.
The company has defined a territory of interest that includes those therapeutic areas that maintain a certain synergy with the company’s growth. The aim is to bet on the future of science in our country, promoting access to the market for biotechnological and/or innovative projects to cover unmet health needs.
Territory of interest
Although we are open to consider all opportunities within the health sector, a territory of interest has been narrowed down as follows:
- Infectious diseases:
New therapeutic alternatives
Reprofiling of medicines
Projects that covers a therapeutic need by the administration of new generation probiotics.
ERN Laboratories is a leader in paediatrics and has extensive knowledge in this sector. For this reason, we are committed to the generation of new products for this type of patient.
Sustainability in the pharmaceutical industry:
We are open to consider packaging, manufacturing, or other alternatives that could help to the sustainability of the products and the company.
Laboratorios ERN, S.A. differentiates its partnerships and/or investments into two types:
Since the beginning of this new stage in R&D&I, Laboratorios ERN, S.A. has invested in two start-ups, and is currently collaborating with a centre of scientific excellence, IBEC (Institute for Bioengineering of Catalonia), for the development of a medical device for wound healing.
At the same time, it has participated in programmes to promote research and technology transfer, such as:
Centres of excellence
Institute for Bioengineering of Catalonia (IBEC)
One of the most important problems in the field of wounds, especially chronic wounds, is the difficulty in achieving good healing and the high rate of recurrence. This usually affects people over 60 years of age with associated diseases, such as vascular diseases, diabetes, etc. During wound healing, the lack of vascularization means that cells cannot reach the area to be regenerated, and the lack of oxygen and nutrients affects the rest of the cells, causing cell death and preventing closure.
The aim of this collaborative project between ERN and IBEC, a public research centre of excellence, is the design and development of a new formulation of a new active ingredient for the treatment of chronic wounds.
With the support of ACCIÓ
Start-ups and Spin-off
Biopharmaceutical company committed to an innovative development based on polymeric conjugates that selectively remove specific antibodies involved in infectious and autoimmune diseases, blood type matching, allergy disorders and improvement of gene therapy.
The company is in a clinical phase, and is a spinoff of IDIBELL.
They currently have two groups of polymeric glycoconjugates protected for different indications: treatment of bacterial infections and autoimmune diseases / allergies, respectively.
This technology combines synthetic biology and computational biology offering a diagnostic kit capable of detecting bacterial RNA in clinical samples in patients suspected of sepsis quickly and with a competitive cost. By quickly identifying the bacteria causing the infection and related resistances, Moirai gives access to the patient to the most appropriate treatment as quickly as possible. By doing so, they want to reduce mortality caused by sepsis by 80%, saving hundreds of millions of euros each year to the health systems.
Thus, these diagnostic kits have been developed thanks to an RNA-based technology, called RNA Plug & Play, which Moirai has designed and patented, based on biosensors capable to detect the characteristics of the infection and performing a good diagnosis to the patient.
Contact us for more information